Apricus Biosciences Announces Corporate Update and Third Quarter 2015 Financial Results Conference Call
SAN DIEGO, 2015-11-02 13:00 CET (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's third quarter 2015 financial results will be released on Thursday, November 5, 2015 after the market close. Company management will host a conference call on Thursday, November 5, 2015, at 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 69492656. The live audio webcast can be accessed via the Investors section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus recently completed enrollment in its Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus has completed a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud's phenomenon, and plans to conduct additional clinical trials in patients with Raynaud's phenomenon secondary to scleroderma. Apricus' lead commercial product, Vitaros®/™, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus recently in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus' marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals) and Mylan NV. Apricus' second-generation room temperature Vitaros is currently under development.
For further information on Apricus, visit http://www.apricusbio.com.
CONTACT: Institutional / Retail Investors: Matthew Beck
The Trout Group LLC
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Global Smart Lock Leader ASSA ABLOY joins Z-Wave Alliance Board of Directors12.12.2017 15:00 | Pressemelding
ASSA ABLOY takes a leadership role in the Alliance to help further Z-Wave adoption and to support global sales of Z-Wave Smart Door Locks FREMONT, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- The Z-Wave Alliance, an open consortium of leading global companies deploying the Z-Wave smart home standard, today announces the addition of ASSA ABLOY to the Alliance Board of Directors. Owner of leading and trusted lock brands such as Yale, Mul-T-Lock and ABLOY, ASSA ABLOY joins principal members ADT, Alarm.com, FIBARO, Huawei, Ingersoll-Rand, Jasco Products, LEEDARSON, LG Uplus, Nortek Security & Control, SmartThings, and Sigma Designs. "ASSA ABLOY was already a leader in the smart lock industry and is clearly making moves to become a global force in smart security and connected access control," said Mitchell Klein, Executive Director of the Z-Wave Alliance, "The entire Alliance will benefit from ASSA ABLOY's contribution to the Board of Directors a
Ammo Incorporated Releases STREAK Visual Ammunition12.12.2017 15:00 | Pressemelding
SCOTTSDALE, Ariz., Dec. 12, 2017 (GLOBE NEWSWIRE) -- AMMO, Inc. (OTC:POWW), a technology leader and premier American ammunitions manufacturer, today announced its newest product offering, STREAK Visual Ammunition. AMMO, Inc. holds the exclusive worldwide rights for the incredible patented technology used to make the STREAK products. STREAK is one of the most technologically advanced ammunition to hit the market in decades. "We are beyond excited to bring STREAK Visual Ammunition to the market. Our acquisition of the exclusive rights for the STREAK technology is a game changer for both our company as well as the shooting industry. Once you shoot with STREAK and you can actually see your projectile travel throughout its path, you will be bored by shooting normal ammunition," said AMMO, Inc.'s CEO, Fred Wagenhals. Unlike conventional tracers, STREAK rounds are NOT an incendiary, they don't use burning metals to generate light. Replacing fire-hazard burning metals is a non
Neato Appoints New CEO Matt Petersen12.12.2017 15:00 | Pressemelding
NEWARK, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Neato Robotics, leader in smart robots for the home, today announced the appointment of new CEO Matt Petersen, effective January 1st, 2018. Petersen has sat on the Neato board since 2014. Petersen currently is the Senior Vice President and Chief Marketing Officer of JAFRA Cosmetics International, a Vorwerk owned subsidiary. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6271e9c8-ac52-402c-9245-9e05fcb4ca36 Current CEO, Giacomo Marini, will step down after five years. Under his tenure, Neato has grown substantially and has launched innovative products with cutting edge technology, including the full Botvac Connected product line of robot vacuums. The tremendous amount of success during this period led to the acquisition by Vorwerk. Marini has been a Director at Neato since 2006, Chairman since 2007, Executive Chairman 2011-2013, and Chairman and CEO
Williams Scotsman to Acquire Acton Mobile12.12.2017 14:05 | Pressemelding
Expands Williams Scotsman's position as a specialty rental services market leader providing innovative modular space and portable storage solutions across North America Williams Scotsman will have nearly 100,000 modular space and portable storage units serving approximately 35,000 customers from over 100 locations across the United States, Canada and Mexico BALTIMORE, Dec. 12, 2017 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman") today announced that it has entered into a definitive agreement whereby Williams Scotsman International, Inc. will acquire the entity that owns Acton Mobile (ActonMobile.com) from Prophet Equity for a cash purchase price of $235 million, subject to customary adjustments. Brad Soultz, president and chief executive officer of Williams Scotsman, commented, "We are excited to welcome Acton to the Williams Scotsman family. Acton shares our core values, and is highly compl
Nature's Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-112.12.2017 13:30 | Pressemelding
CALGARY, Alberta, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that a recent Nature Scientific Reports has published a 12 page publication on BET (bromodomain and extra-terminal) inhibitors; RVX-208 (apabetalone) and PFI-1 owned by Resverlogix and Pfizer, respectively. The publication by Lu et al, "BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency", (Scientific Reports 7, Article number: 16646, https://www.nature.com/articles/s41598-017-16816-1) demonstrates that both BET inhibitors can reactivate HIV-1 from latency. Persistent latent reservoirs of HIV-1 in resting CD4+T cells are the major obstacle in curing HIV-1 infection. Their conclusion suggests that BET inhibitors, such as apabetalone (RVX-208), are a group of leading compounds for potentially unmasking HIV-1 latency to allow for viral eradication. Mr. Donald McCaffrey, President and Chief Executive Officer commented, "We are thrilled to lear
ILPA Issues Model Subscription Agreement for Private Equity Funds12.12.2017 13:00 | Pressemelding
Fund Document Developed to Increase Clarity, Reduce Costs and Time to Close WASHINGTON and TORONTO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- In an effort to streamline fundraising, increase clarity and improve the efficiency of capital formation, the Institutional Limited Partners Association (ILPA) today released a model subscription agreement (MSA) for private equity funds. Developed by legal counsels representing the private equity industry, the modular, multi-jurisdictional document provides a balanced, off-the-shelf solution which can be easily customized to meet the needs of fund managers and their investors, saving significant time and cost. The ILPA MSA is available to the industry on the ILPA website. "In speaking to private equity stakeholders about legal procedures in need of streamlining, the fund closing process was at the top of the list for constructive disruption," said Chris Hayes, Director of Industry Affairs, ILPA. "Both LPs
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom